Femarelle Recharge - Non Hormonal Natural Menopause Supplements for Women -1 Month Supply

Published Studies Femarelle

1. Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. J. of Clin Exper Obstet Gynecol2004; 31(2):123-26
2. Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. J Endocrinol. Invest. 2013; 36(7):521-6
3. Genazzani AR et al. Brain region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. Menopause2009; 16(5):1037-43
4. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. Menopause book of abstract of the NAMS 22nd Annual Meeting, Sept, 2011, p. 55
5. Yoles I. et al. Tofupill/Femarelle (DT56a) - a New Phyto-Selective Estrogen Receptor Modulator-like Substance for the Treatment of Postmenopausal Bone Loss. Menopause2003; 10(6):522-25
6. Somjen D, Yoles I. DT56a (Tofupill/Femarelle), selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J. of Steroid Biochemistry & Molecular Biology 2003; 86(1):93-98
7. Somjen D. et al. DT56a (Femarelle/Tofupill) Stimulates Bone Formation in Female Rats. British J. of Obstetrics & Gynecology 2005; 112(7):981-85
8. Somjen D., Katzburg S. Lieberherr M., Hendel D., Yoles I. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In Vitro. J. of Steroid Biochemistry & Molecular Biology2006; 98(1):90-96
9. Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. J Endocrinol Invest. 2011;34(2):106-10
10. Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. European J. of Obstetrics & Gynecology & Reproductive Biology 2006; 130(1):140-141
11. Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011;18(3):285-288
12. Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. Reproductive Toxicology 2005; 20(2):261-66
13. Somjen D, Yoles I. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). J. of Steroid Biochemistry & Molecular Biology 2007;104:252-58
14. Somjen D. et al. DT56a (Femarelle); is effective in human derived female osteoblasts in hyperglycemic condition. J Steroid Biochem Mol Biol. 2011; 123:25-29
15. Bedell S., Nachtigall M., Naftolin F. The pros and cons of plant estrogens for menopause; J. Steroid Biochem. Mol. Biol. 2014;139:225-236
16. Sánchez-Borrego R, Mendoza N, Llaneza P. A prospective study of DT56a (Femarelle) for the treatment of menopause symptoms. Climacteric. 2015;18(6):813-6
17. Sánchez-Borrego R. et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy; Climacteric. 2015 Jun;18(3):350-7
18. Chen FP et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. Taiwan J Obstet Gynecol. 2016 Jun; 55(3):336-40
19. Somjen D, Yoles I.: "DT56a stimulates creatine kinase specific activity in vascular tissues of rats. J. of Endocrinological Investigation 2003;26(10):966-971
20. Somjen D. et al. Interaction between the effects of the selective estrogen modulator Femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells. J Steroid Biochem Mol Biol. 2017;174:9-13
21. Genazzani AR. DT56a, a non-hormonal botanical therapy, as first line treatment for menopausal symptoms. 12th European Society of Gynecology Congress, Opening Symposium - Climacteric and Menopause: from symptoms to therapies, from security to efficacy; October 18, 2017